Malaria in Pregnancy: Prevention

Overview

Malaria in pregnancy carries substantially higher maternal and fetal risk than in non-pregnant adults — increased risk of severe disease, anaemia, miscarriage, stillbirth, preterm birth and low birth weight. Prevention is built around the "ABCD" framework: Awareness of risk, Bite avoidance, Chemoprophylaxis, and prompt Diagnosis and treatment if illness occurs (diagnosis/treatment is covered separately in GTG 54b).

Travel Advice

• Pregnant women should be advised, wherever possible, to avoid or postpone travel to malaria-endemic areas until after pregnancy.
• If travel is unavoidable, women should seek pre-travel advice from a specialist in travel medicine or a health professional with expertise in malaria prevention, ideally well in advance of departure.
• Risk assessment should take into account the specific destination, itinerary, season, local drug-resistance patterns, and duration of stay.

Bite Avoidance

Pregnant women may be more attractive to mosquitoes and should be counselled that bite avoidance is a cornerstone of prevention, day and night:

• Use insect repellent containing DEET (diethyltoluamide, up to 50% concentration) on exposed skin — DEET is considered safe for use in pregnancy and while breastfeeding.
• Sleep under a permethrin-treated mosquito net that is intact and correctly tucked in.
• Wear long sleeves, long trousers and socks, particularly from dusk onwards, when the principal malaria vector (Anopheles) is most active.
• Use knockdown insecticide sprays or plug-in vaporisers in sleeping areas, and stay in accommodation with screened windows/doors or air conditioning where possible.
• Unproven or herbal/homeopathic "repellents" should not be relied upon.

Chemoprophylaxis in Pregnancy

• Chemoprophylaxis choice must balance the risk of malaria (particularly Plasmodium falciparum, which carries the highest risk of severe disease in pregnancy) against the drug's safety profile in pregnancy, and should always be individualised with specialist input.
• Some established antimalarial agents have a long track record of use in pregnancy and are generally considered acceptable in appropriate destinations, while others are avoided because of known or theoretical fetal risk (e.g. agents affecting fetal bone/tooth development, or those with teratogenic potential in early pregnancy).
• Choice of agent depends heavily on local drug-resistance patterns at the destination, gestation, and maternal comorbidities (e.g. history of epilepsy or psychiatric illness may preclude certain options) — specialist/travel medicine advice should always be sought rather than relying on generic advice, and up-to-date resistance data should be checked, as recommendations change over time.
• Women should be advised that no chemoprophylactic regimen is 100% protective — bite avoidance remains essential even when taking prophylaxis.
• Chemoprophylaxis does not need to be stopped for breastfeeding for most first-line agents, but this should be confirmed with a specialist, and some agents are specifically not recommended while breastfeeding.

Key Message

Prevention is preferable to treatment: the safest approach for a pregnant woman is to avoid travel to malaria-endemic areas altogether; where travel is unavoidable, rigorous bite avoidance plus individualised, specialist-guided chemoprophylaxis substantially reduces — but does not eliminate — risk.

High-Yield Exam Points

• ABCD framework: Awareness, Bite avoidance, Chemoprophylaxis, Diagnosis/treatment.
• First-line advice for pregnant women is to avoid or postpone travel to endemic areas; specialist travel-medicine input is needed if travel is unavoidable.
• DEET up to 50% is considered safe in pregnancy and breastfeeding for bite avoidance.
• P. falciparum poses the greatest risk of severe maternal and fetal disease among the malaria species.
• No chemoprophylactic regimen offers complete protection — bite avoidance must continue alongside any drug regimen.
• Chemoprophylaxis choice is individualised (destination resistance patterns, gestation, comorbidities such as epilepsy/psychiatric history) and should involve specialist advice rather than a fixed drug list.
• This guideline (2010) is one of the oldest unrevised Green-tops still in active use — ACMP/UKHSA now hold current prescribing guidance, a useful "guideline governance" fact for Part 1/2 questions on evidence sources.
• GTG 54b (a separate, companion guideline) covers diagnosis and treatment of malaria once contracted — do not conflate prevention (54a) with treatment (54b) in exam answers.

Source: RCOG Green-top Guideline No. 54a (First published April 2010. Not revised since; RCOG notes the Advisory Committee on Malaria Prevention (ACMP) has since agreed to assume ownership and update it — treat drug-specific advice as potentially superseded by current UKHSA/ACMP guidance.)

Read the original on rcog.org.uk

Clinically reviewed by NHS obstetricians and gynaecologists · Source last updated First published April 2010. Not revised since; RCOG notes the Advisory Committee on Malaria Prevention (ACMP) has since agreed to assume ownership and update it — treat drug-specific advice as potentially superseded by current UKHSA/ACMP guidance.

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).